Bure Equity AB (publ) BURE
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing position can be maintained pending further confirmation of portfolio development.
Strong NAV growth during the period but subsequent price reactions and continued dependence on individual portfolio companies support a continued neutral stance.
The market reacts neutrally to positively on the strong portfolio development but is tempered by macro concerns around AI and tech after the reporting period.
HOLD is the call. Positive is the market mood. Medium risk means some things can go wrong.
Latest change
- 6 Jun 2026 — The latest analysis adds Q1 reporting: a weak quarter (NAV −9% YTD and a large net loss) followed by a clear post-quarter NAV rebound.
About the company
Bure Equity is an investment company focused on long-term ownership in Nordic companies with emphasis on technology and healthcare. The portfolio is dominated by listed holdings such as Mycronic, Vitrolife, Silex Microsystems and Xvivo Perfusion. Value development is driven by the share price performance of portfolio companies and net asset value.
Bull case
Several core holdings such as Mycronic and Yubico deliver strong growth and contribute to continued NAV appreciation.
Bear case
High concentration in a few large holdings makes the company sensitive to share price movements in individual portfolio companies.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| Mycronic share price | Mycronic share price falls sharply → net asset value declines rapidly and the discount may widen. | Mycronic share price continues to rise → net asset value increases further and may lead to a premium. |
| Silex Microsystems development | Silex performs weakly after listing → contribution to NAV decreases and negatively affects total return. | Silex continues strongly → additional value increase in the portfolio and strengthened confidence in the listing strategy. |
Why this signal
Strong NAV growth during the period but subsequent price reactions and continued dependence on individual portfolio companies support a continued neutral stance.
Recent news
Bure released its Q3 report on November 5 showing strong NAV growth to 360 SEK per share. Post-report NAV fell to 334 SEK per share on November 4 due to concerns over AI investments affecting holdings such as Silex and Xvivo. Mycronic raised its full-year guidance and Yubico showed strong performance.